Canterbury DHB

Context

Minor Bleeds

Most patients with Type I von Willebrand disease can be managed with desmopressin. Desmopressin increases factor VIII levels to a similar or greater extent than in patients with mild haemophilia and shortens or normalises the skin bleeding time and platelet function assay (PFA-100). Some, but not all, Type IIA VWD patients respond to desmopressin. In Type IIB disease desmopressin fails to shorten the bleeding time and may produce a severe transient thrombocytopenia. Desmopressin is contraindicated in Type IIB VWD and pseudo-von Willebrand disease. It is useless in Type III VWD.

See the Desmopressin Data Sheets on Medsafe for dosage, precautions, side effects and contraindications.

About this Canterbury DHB document (5277):

Document Owner:

Mark Smith (see Who's Who)

Issue Date:

August 2016

Next Review:

August 2019

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 5277